CA2131350C - Sustained release drug formulation containing a tramadol salt - Google Patents
Sustained release drug formulation containing a tramadol salt Download PDFInfo
- Publication number
- CA2131350C CA2131350C CA002131350A CA2131350A CA2131350C CA 2131350 C CA2131350 C CA 2131350C CA 002131350 A CA002131350 A CA 002131350A CA 2131350 A CA2131350 A CA 2131350A CA 2131350 C CA2131350 C CA 2131350C
- Authority
- CA
- Canada
- Prior art keywords
- weight
- release
- active ingredient
- drug formulation
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000013583 drug formulation Substances 0.000 title claims abstract description 25
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical class COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims abstract description 18
- 238000013268 sustained release Methods 0.000 title description 5
- 239000012730 sustained-release form Substances 0.000 title description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 24
- 230000002459 sustained effect Effects 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 29
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 229920003086 cellulose ether Polymers 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229960004380 tramadol Drugs 0.000 claims description 5
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 53
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 238000000034 method Methods 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 239000000945 filler Substances 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 8
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 8
- 235000019700 dicalcium phosphate Nutrition 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 229960003107 tramadol hydrochloride Drugs 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000000576 coating method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000007939 sustained release tablet Substances 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000007892 solid unit dosage form Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940038625 tramadol hydrochloride 100 mg Drugs 0.000 description 2
- 229940091845 tramadol hydrochloride 150 mg Drugs 0.000 description 2
- 229940038613 tramadol hydrochloride 200 mg Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003455 independent Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4329794.3 | 1993-09-03 | ||
| DE4329794A DE4329794C2 (de) | 1993-09-03 | 1993-09-03 | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2131350A1 CA2131350A1 (en) | 1995-03-04 |
| CA2131350C true CA2131350C (en) | 2005-08-16 |
Family
ID=6496771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002131350A Expired - Lifetime CA2131350C (en) | 1993-09-03 | 1994-09-01 | Sustained release drug formulation containing a tramadol salt |
Country Status (27)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7074430B2 (en) | 1993-05-10 | 2006-07-11 | Euro-Celtique S.A. | Controlled release tramadol tramadol formulation |
| US8980291B2 (en) | 1999-10-29 | 2015-03-17 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
| US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
| US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
| US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
| KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
| US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
| GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| DE19530575A1 (de) * | 1995-08-19 | 1997-02-20 | Gruenenthal Gmbh | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz |
| GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
| PT888111E (pt) * | 1996-03-08 | 2003-09-30 | Nycomed Danmark As | Composicao de multiplas unidades de dosagem de libertacao modificada. |
| DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| DE19712398A1 (de) * | 1997-03-25 | 1998-10-01 | Gruenenthal Gmbh | Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel |
| DE69834195T2 (de) * | 1997-07-02 | 2007-03-29 | Euro-Celtique S.A. | Stabilisierte tramadol formulierungen mit verzögerter freisetzung |
| US6156342A (en) * | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
| DE29818454U1 (de) * | 1998-10-15 | 1999-01-14 | Euroceltique S.A., Luxemburg/Luxembourg | Opioid-Analgetikum |
| US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
| AU3469100A (en) * | 1999-01-05 | 2000-07-24 | Copley Pharmaceutical Inc. | Sustained release formulation with reduced moisture sensitivity |
| DE19901686A1 (de) * | 1999-01-18 | 2000-07-20 | Gruenenthal Gmbh | Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung |
| DE19901692C2 (de) * | 1999-01-18 | 2002-06-20 | Gruenenthal Gmbh | Verfahren zur Herstellung von Pellets mit einem Gehalt von bis zu 90 Gew.% eines pharmazeutischen Wirkstoffes |
| DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| ATE279186T1 (de) * | 1999-08-31 | 2004-10-15 | Gruenenthal Gmbh | Retardierte darreichungsform enthaltend tramadolsaccharinat |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| SK285128B6 (sk) * | 1999-12-28 | 2006-07-07 | Zentiva, A. S. | Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy |
| RU2165922C1 (ru) * | 2000-07-19 | 2001-04-27 | Государственный научно-исследовательский институт органической химии и технологии | Способ получения трамадола |
| PT1190712E (pt) * | 2000-09-22 | 2005-01-31 | Smb Technology | Composicao de esferas de tramadol para administracao oral uma vez por dia |
| AU2002223572B2 (en) * | 2000-09-29 | 2005-09-08 | Abbvie B.V. | Ion-strength independent sustained release pharmaceutical formulation |
| KR20030051760A (ko) | 2000-10-30 | 2003-06-25 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| RU2174836C1 (ru) * | 2000-12-15 | 2001-10-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция, обладающая анальгезирующим действием |
| DE10108122A1 (de) * | 2001-02-21 | 2002-10-02 | Gruenenthal Gmbh | Arzneimittel auf Basis von Tramadol |
| ATE326957T1 (de) | 2001-03-16 | 2006-06-15 | Dmi Biosciences Inc | Verwendung von tramadol zur verzögerung der ejakulation |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| US8128957B1 (en) * | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
| US20060099249A1 (en) * | 2002-02-21 | 2006-05-11 | Pawan Seth | Modified release formulations of at least one form of tramadol |
| WO2003077897A1 (en) * | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| WO2003080031A1 (en) * | 2002-03-22 | 2003-10-02 | Cilag Ag | Sustained release formulation of tramadol |
| DE10224108A1 (de) * | 2002-05-29 | 2004-01-29 | Grünenthal GmbH | 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung |
| US7410965B2 (en) | 2002-05-29 | 2008-08-12 | Gruenenthal Gmbh | Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol |
| US7776314B2 (en) * | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| EP1545468A4 (en) * | 2002-09-20 | 2007-06-20 | Alpharma Inc | SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE |
| US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
| US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| MXPA05008033A (es) * | 2003-01-28 | 2006-04-28 | Collegium Pharmaceutical Inc | Composiciones de milnacipran en forma de multiparticulas para administracion oral. |
| DE10333835A1 (de) * | 2003-07-24 | 2005-03-10 | Gruenenthal Gmbh | 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| EP1842533B1 (de) * | 2003-08-06 | 2013-05-01 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102004032051A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| US20050089558A1 (en) * | 2003-10-28 | 2005-04-28 | Alamo Pharmaceuticals, Llc | Compositions and methods for the co-formulation and administration of tramadol and propoxyphene |
| DE102004032103A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102004032049A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| ITMI20050391A1 (it) * | 2005-03-11 | 2006-09-12 | Ph & T S P A | Formulazioni a rilascio controllato di alfuzosin |
| WO2007008752A2 (en) * | 2005-07-07 | 2007-01-18 | Farnam Companies, Inc. | Sustained release pharmaceutical compositions for highly water soluble drugs |
| CA2616204C (en) | 2005-09-09 | 2015-12-01 | Labopharm Inc. | Sustained drug release composition |
| AU2006308449B8 (en) * | 2005-09-09 | 2012-11-22 | Angelini Labopharm, Llc | Trazodone composition for once a day administration |
| US20090104266A1 (en) * | 2005-09-15 | 2009-04-23 | Tobias Jung | 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation |
| US8691272B2 (en) * | 2005-12-30 | 2014-04-08 | Intelgenx Corp. | Multilayer tablet |
| US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
| US20080020032A1 (en) * | 2006-07-21 | 2008-01-24 | Michael Crowley | Hydrophobic abuse deterrent delivery system for hydromorphone |
| DE102006044694A1 (de) * | 2006-09-22 | 2008-03-27 | Krewel Meuselbach Gmbh | Perorale feste Schmerzmittelzubereitung |
| SG178775A1 (en) | 2007-02-12 | 2012-03-29 | Dmi Biosciences Inc | Reducing side effects of tramadol |
| EP2120570B1 (en) | 2007-02-12 | 2012-05-16 | DMI Biosciences, Inc. | Treatment of comorbid premature ejaculation and erectile dysfunction |
| DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| RU2469718C2 (ru) * | 2007-10-16 | 2012-12-20 | Лабофарм Инк. | Двухслойная композиция для непрерывного высвобождения ацетаминофена и трамадола |
| CN101969930A (zh) | 2007-12-17 | 2011-02-09 | 莱博法姆公司 | 防滥用控制释放制剂 |
| BRPI0906467C1 (pt) | 2008-01-25 | 2021-05-25 | Gruenenthal Gmbh | forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada |
| DK2273983T3 (en) * | 2008-05-09 | 2016-09-19 | Gruenenthal Gmbh | A process for the preparation of a powdery formulation intermediate and a fixed final dosage form using a sprøjtestørkningstrin |
| US20100003322A1 (en) * | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
| CA2746888C (en) * | 2008-12-16 | 2015-05-12 | Labopharm (Barbados) Limited | Misuse preventative, controlled release formulation |
| WO2011009603A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Tamper-resistant dosage form for oxidation-sensitive oploids |
| CN102573805A (zh) | 2009-07-22 | 2012-07-11 | 格吕伦塔尔有限公司 | 热熔挤出的控制释放剂型 |
| US20110136815A1 (en) * | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
| US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
| CN102821757B (zh) * | 2010-02-03 | 2016-01-20 | 格吕伦塔尔有限公司 | 通过挤出机制备粉末状药物组合物 |
| WO2011141489A1 (en) | 2010-05-10 | 2011-11-17 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
| JP6005636B2 (ja) | 2010-07-06 | 2016-10-12 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形 |
| PE20131102A1 (es) | 2010-09-02 | 2013-10-12 | Gruenenthal Chemie | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica |
| JP5933553B2 (ja) | 2010-09-02 | 2016-06-15 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | アニオン性ポリマーを含む不正使用抵抗性剤形 |
| US20120202838A1 (en) * | 2010-11-04 | 2012-08-09 | Abbott Laboratories | Drug formulations |
| MX348054B (es) | 2011-07-29 | 2017-05-25 | Gruenenthal Gmbh | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco. |
| RS56528B1 (sr) | 2011-07-29 | 2018-02-28 | Gruenenthal Gmbh | Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu |
| MX356421B (es) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico. |
| WO2013156453A1 (en) | 2012-04-18 | 2013-10-24 | Grünenthal GmbH | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| EP3003279A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| BR112015029616A2 (pt) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | forma de dosagem resistente à adulteração com perfil de liberação bimodal |
| EA032465B1 (ru) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления |
| EP3073994A1 (en) | 2013-11-26 | 2016-10-05 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| EP3148512A1 (en) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| EA035434B1 (ru) | 2015-04-24 | 2020-06-15 | Грюненталь Гмбх | Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями |
| CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| JPS5492631A (en) * | 1977-12-27 | 1979-07-23 | Kowa Co | Analgestic |
| US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| EP0147780A3 (en) * | 1984-01-03 | 1987-03-11 | Merck & Co. Inc. | Drug delivery device |
| US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| FR2618073B1 (fr) * | 1987-07-16 | 1990-09-07 | Pf Medicament | Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation |
| DE3830353A1 (de) * | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| US5268181A (en) * | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
| JPH04217925A (ja) * | 1990-03-27 | 1992-08-07 | Nippon Saafuakutanto Kogyo Kk | 新規な解熱消炎鎮痛剤組成物 |
| IL109460A (en) * | 1993-05-10 | 1998-03-10 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
| DE4315525B4 (de) * | 1993-05-10 | 2010-04-15 | Euro-Celtique S.A. | Pharmazeutische Zusammensetzung |
-
1993
- 1993-09-03 DE DE4329794A patent/DE4329794C2/de not_active Expired - Fee Related
-
1994
- 1994-05-26 IL IL10980094A patent/IL109800A/xx not_active IP Right Cessation
- 1994-07-11 UY UY23804A patent/UY23804A1/es not_active IP Right Cessation
- 1994-07-19 PE PE1994246995A patent/PE10195A1/es not_active IP Right Cessation
- 1994-07-22 MY MYPI94001903A patent/MY111754A/en unknown
- 1994-08-24 DK DK94113192T patent/DK0642788T3/da active
- 1994-08-24 SI SI9430142T patent/SI0642788T1/xx unknown
- 1994-08-24 EP EP94113192A patent/EP0642788B1/de not_active Expired - Lifetime
- 1994-08-24 AT AT94113192T patent/ATE166575T1/de active
- 1994-08-24 DE DE59406075T patent/DE59406075D1/de not_active Expired - Lifetime
- 1994-08-24 ES ES94113192T patent/ES2119034T3/es not_active Expired - Lifetime
- 1994-08-25 EC EC1994001148A patent/ECSP941148A/es unknown
- 1994-08-29 HU HU9402478A patent/HU215955B/hu unknown
- 1994-09-01 KR KR1019940021959A patent/KR100325494B1/ko not_active Expired - Lifetime
- 1994-09-01 RU RU94032150A patent/RU2138253C1/ru active
- 1994-09-01 JP JP20895794A patent/JP3954117B2/ja not_active Expired - Lifetime
- 1994-09-01 CA CA002131350A patent/CA2131350C/en not_active Expired - Lifetime
- 1994-09-01 BR BR9403030A patent/BR9403030A/pt not_active Application Discontinuation
- 1994-09-01 PL PL94304860A patent/PL177315B1/pl unknown
- 1994-09-02 ZA ZA946775A patent/ZA946775B/xx unknown
- 1994-09-02 CN CN94115648A patent/CN1092956C/zh not_active Expired - Lifetime
- 1994-09-02 CO CO94039369A patent/CO4290295A1/es unknown
- 1994-09-02 AU AU72803/94A patent/AU671384B2/en not_active Expired
- 1994-09-02 FI FI944035A patent/FI113336B/fi not_active IP Right Cessation
- 1994-09-02 LT LTIP2033A patent/LT3664B/lt not_active IP Right Cessation
- 1994-09-02 UA UA94095777A patent/UA26455C2/uk unknown
- 1994-09-05 CZ CZ19942140A patent/CZ288832B6/cs not_active IP Right Cessation
-
1996
- 1996-01-16 US US08/585,741 patent/US5601842A/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7074430B2 (en) | 1993-05-10 | 2006-07-11 | Euro-Celtique S.A. | Controlled release tramadol tramadol formulation |
| US8980291B2 (en) | 1999-10-29 | 2015-03-17 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| US9056107B1 (en) | 1999-10-29 | 2015-06-16 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| US9278074B2 (en) | 1999-10-29 | 2016-03-08 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| US9320717B2 (en) | 1999-10-29 | 2016-04-26 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2131350C (en) | Sustained release drug formulation containing a tramadol salt | |
| US11007156B2 (en) | Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol | |
| US8637512B2 (en) | Formulations and method of treatment | |
| AU2003260336C1 (en) | Sustained release formulations comprising lamotrigine | |
| AU2002322964B2 (en) | Dosage forms having prolonged active ingredient release | |
| TW200302741A (en) | Oral controlled release forms useful for reducing or preventing nicotine cravings | |
| HUP0203334A2 (hu) | Közvetlen kompresszióval előállított polimer tabletta magok | |
| AU2002322964A1 (en) | Dosage forms having prolonged active ingredient release | |
| CN102596183B (zh) | 迅速溶出/崩解的包衣组合物 | |
| US20050281873A1 (en) | Universal controlled-release composition | |
| US20070160667A1 (en) | Controlled release formulation of divalproex sodium | |
| AU709413B2 (en) | Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants | |
| AU2006335344A1 (en) | Controlled release formulation of divalproic acid and its derivatives | |
| CA2739611C (en) | Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient | |
| HK1010447B (en) | Tramadol salt containing medicaments with sustained release of the active ingredient | |
| AU2007202294A1 (en) | Sustained release formulations comprising lamotrigine | |
| HK1105891A (en) | Controlled release formulation of divalproic acid and its derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20140902 |